Understanding hand function issues in systemic sclerosis
Official title: Hand Function Impairment in Systemic Sclerosis: Outcomes, Mechanisms and Experience (HANDSOME) Study
Run by UMC Utrecht · NCT06133244 · Data updated 2026-11-12
This study looks at how systemic sclerosis affects hand function in patients to see what causes problems and how to better manage them.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | UMC Utrecht Academic / other |
| Locations | 1 site (Utrecht) |
| Status | Recruiting |
| Started | April 19, 2024 |
| Main results expected | April 2028 |
| Study ends | April 2028 |
| Registry record updated | May 28, 2024 |
| Trial ID | NCT06133244 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults over 18 years diagnosed with systemic sclerosis.
✕Probably not a fit
Patients with diabetic cheiroarthropathy or Dupuytren's disease may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on patients with systemic sclerosis (SSc) to explore the outcomes, mechanisms, and experiences related to hand function impairment. It aims to investigate the processes leading to limitations in hand function, particularly due to contractures, which affect a significant number of patients. The study will utilize imaging, blood samples, functional tests, and physical examinations to gather comprehensive data over time. By following a longitudinal cohort, the researchers hope to gain insights that could inform better management strategies for affected individuals.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of hand function impairments in systemic sclerosis patients.
How similar studies have gone: While there have been studies on systemic sclerosis, this specific focus on hand function impairment and its mechanisms is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years Exclusion Criteria: * Patients with diabetic cheiroarthropathy and Dupuytren's disease, based on expert opinion
Where it's running
-
UMC Utrecht
Utrecht, Netherlands Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Test of HBM7020 in healthy adults and adults with autoimmune diseases
This first-in-human study tests whether HBM7020 is safe and how it acts in the body for people with autoimmune diseases like RA, SLE, Sjögren's, and SSc compared with healthy volunteers.
-
Anti-CD19/BCMA universal CAR-T cell therapy for refractory autoimmune diseases
This will try anti-CD19/BCMA universal CAR-T cell therapy in adults with refractory rheumatoid arthritis, dermatomyositis, systemic lupus, or systemic sclerosis to see if it is safe and can control their disease.
-
Immun4Cure Cohort of Autoimmune Diseases
A long-term, 500-person database and biobank is being built to study autoimmune diseases like RA, SLE, and scleroderma, plus healthy adults, using deep profiling and regular follow-ups over five years.
-
Nerandomilast for Systemic Sclerosis in Adults
This study tests whether nerandomilast tablets can help adults with systemic sclerosis compared to a placebo.
-
AZD0120 CD19/BCMA CAR T-cell therapy for systemic sclerosis, inflammatory myopathies, and difficult-to-treat rheumatoid arthritis
This trial will try a dual-targeting CD19/BCMA CAR T-cell treatment (AZD0120) in adults with systemic sclerosis, idiopathic inflammatory myopathies, or difficult-to-treat rheumatoid arthritis to see if it is safe and well tolerated.
-
Phase 1 safety test of XmAb657 in healthy adults and people with myositis, scleroderma, or Sjögren's
This study will test whether subcutaneous injections of XmAb657 are safe and well tolerated in healthy adults and people with autoimmune diseases such as idiopathic inflammatory myopathies, systemic sclerosis, or primary Sjögren's syndrome.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.